With the addition of Ganirelix, Ferring continues to offer the most complete reproductive medicine portfolio available, which includes Menopur (menotropins for injection), NOVAREL (chorionic gonadotropin for injection, USP) and Endometrin (progesterone) Vaginal Insert.
Ganirelix is a GnRH antagonist used to prevent premature luteinizing hormone surges in women undergoing fertility treatment.
On November 30, 2018, Sun Pharma received final approval from the US FDA for its Abbreviated New Drug Application for generic version of Ganirelix Acetate Injection, 250 mcg/0.5 mL.
In addition, Ferring also finalized the transaction with INVO Bioscience Inc. to acquire the exclusive US commercialization rights for the INVOcell Intravaginal Culture System, which comprises the INVOcell Culture Device and Retention Device.
The INVOcell Culture Device uses a woman's own body as an incubator during fertilization and early embryo development.
In 2015, INVO Bioscience received FDA clearance for the INVOcell IVC system, making it the first IVC system marketed in the US.
Through this acquisition, Ferring will use its resources and expertise in the field of assisted reproductive technologies to help reproductive endocrinology practices across the country expand their service offerings to include the IVC procedure, in addition to their current treatment offerings of intrauterine insemination and in vitro fertilization.
In the US, statistics show that over 1.4m women may benefit from advanced fertility treatment. However, only approximately 130,000 people begin such treatment.2
Ferring Pharmaceuticals is a biopharmaceutical company devoted to identifying, developing and marketing innovative products in the fields of reproductive health, women's health, urology, gastroenterology, endocrinology and orthopaedics.
Ganirelix Acetate Injection is used to prevent premature ovulation during controlled ovarian stimulation.
Upsher-Smith launches Glatiramer Acetate Injection generic
Annexin Pharmaceuticals receives proposed INN vanexin for ANXV
Henlius and Sandoz expand biosimilars collaboration
Aurisco Pharmaceutical reports successful US FDA inspection
Dr. Reddy's launches first-to-market sugammadex injection in the US
Par Health launches generic version of Janumet XR tablets in US
EQL Pharma gains approval to sell Mellozzan in Kazakhstan
Newbury Pharmaceuticals receives Swedish approval for generic tofacitinib
Breckenridge launches Tofacitinib Tablets, generic equivalent to Pfizer's Xeljanz
Hims & Hers expands GLP-1 offering in Canada with generic semaglutide
Apotex announces commercial launch of Apo-Semaglutide Injection in Canada
Transpire Bio's generic high-strength Trelegy Ellipta ANDA accepted for filing by US FDA
Kaiser Permanente reports study findings showing significant cost savings